By using WTA for viral amplification, both DNA and RNA viruses could be run through the same protocol. The correct DNA or RNA virus was detected in 14 out of 14 samples, representing a diverse set of clinical materials. Moreover, we can correctly detect multiple subtypes of a virus present in a sample, as seen for two clinical samples positive for multiple HPV subtypes (6/16/53/61 and 16/103, respectively), with no cross-hybridization towards other subtypes. Furthermore, EV-A (Coxsackievirus A6) was clearly detected without any cross-hybridization towards any other of the 6 species with several serotypes included in the large Enterovirus genus (EV-B/C/D and Rhinovirus A/B/C). It should be noted that subtype identification was not a goal in the probe design when developing LLMDA, nevertheless, the ability to combine the signals from multiple probes in the analysis made it possible to discriminate between different subtypes [19] . In several samples analysed, more than one virus was found, in some cases including both DNA and RNA viruses. Taken together, this demonstrates the potential and real life utility of the microarray technique for broad-spectrum pathogen detection in clinical samples.